Weiqiang Medical Technology (Shanghai) Co., Ltd., located in Shanghai, China, was reorganized into Cayman Endonom Medical Holding Corporation in February 2019. Combining the innovative advantages of Chinese vascular interventional technology and high efficiency and low cost, the company focuses on the R&D, manufacturing, sales and technical support of peripheral vascular interventional medical devices. Its main products are aortic stent products, venous stent and filter products, drug balloons and adjustable flexible catheters, etc., providing a more safe and effective overall diagnosis and treatment program, giving priority to serving Chinese patients.

In May 2022, the "Thoracic Aortic Stent System" produced by Weiqiang Medical was approved for listing by the State Food and Drug Administration